CHK2 polymorphism as a cancer marker
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 9, 2016
Grant Date -
Jul 5, 2012
app pub date -
Mar 8, 2010
filing date -
Mar 6, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention relates to the use of gene modifications in the human gene CHK2 (CHEK2), which encodes the checkpoint kinase 2, for predicting the risk and progression of cancer diseases, for predicting the response to pharmacological or non-pharmacological therapeutic measures for treating cancer diseases, and for predicting undesired effects of drugs. The invention further relates to the provision of individual gene variants with the help of which further gene modifications that can be used for the aforementioned purposes can be detected and validated. Such gene modifications can comprise a substitution of adenine for guanine in position −7161 in the promoter of CHK2, a substitution of guanine for cytosine in position −7235, a substitution of adenine for guanine in position −10532, or a deletion of 29 base pairs in positions −10621 to −10649.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully